Share
David DeMartino
Zimmer Biomet Holdings, Inc., a global leader in medical technology, has announced that David DeMartino has been appointed as the company’s Senior Vice President, Investor Relations.
DeMartino will report to Ivan Tornos, President and CEO of Zimmer Biomet. In this role, he will be responsible for developing and leading Zimmer Biomet's investor relations strategy and building relationships with the investment and financial community.
Ivan Tornos, President and CEO of Zimmer Biomet, stated, “We are thrilled to welcome David as our new head of investor relations. His impressive career and extensive knowledge of the medtech industry, gained through roles as an investor and in equity research, make him the perfect fit for this crucial role. As we enter an exciting phase for our Company, David will be instrumental in steering our IR initiatives and strengthening our connections with the investment community.”
DeMartino brings over 25 years of experience in the healthcare industry, including asset management, equity research, and investment banking. Prior to joining Zimmer Biomet, he served as Chief Strategy Officer at Nyxoah, a medical technology company focused on Obstructive Sleep Apnea solutions. His previous roles include portfolio manager at DNB Asset Management and senior analyst positions at Velan Capital, Citadel, and Pura Vida Investments, where he covered medical devices, biotechnology, and healthcare technology. DeMartino also has experience in sell-side equity research with Deutsche Bank and Credit Suisse and began his career in Deutsche Bank’s Healthcare investment banking group. He holds a BA in Economics from Washington and Lee University.
